We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Arix Bioscience Plc | LSE:ARIX | London | Ordinary Share | GB00BD045071 | ORD 0.001P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 142.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMARIX
RNS Number : 1565W
Arix Bioscience Plc
10 November 2017
Sir John Banham retires from Board of Directors of Arix Bioscience plc
LONDON, 10 November 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or "the Company"), a global healthcare and life science company supporting medical innovation, today announces that Sir John Banham is retiring from his position as a Non-Executive Director of Arix Bioscience.
Sir John, who is 76, has been Chairman of the Audit and Risk Committee, and has helped to oversee the Company's growth both as a private company and since its successful IPO on the London Stock Exchange in February 2017. As previously announced, Giles Kerr joined the Board of Arix on 17 October 2017 and will succeed Sir John as Chairman of the Audit and Risk Committee.
Jonathan Peacock, Chairman of Arix Bioscience, said: "It has been a pleasure and a privilege to work with Sir John. On behalf of the Board, I would like to thank him for his many contributions to the successful creation and early development of Arix Bioscience."
For more information, please contact:
Arix Bioscience plc
Matthew Cole, Communications Director
+44 (0) 20 7290 1065
Consilium Strategic Communications
Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan
+44 (0)20 3709 5700
arix@consilium-comms.com
About Arix Bioscience plc
Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.
Arix Bioscience plc is listed on the Main Market of the London Stock Exchange. For further information, please visit www.arixbioscience.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAGIBDBISBBGRG
(END) Dow Jones Newswires
November 10, 2017 04:00 ET (09:00 GMT)
1 Year Arix Bioscience Chart |
1 Month Arix Bioscience Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
